VSTM
$1.80
Verastem
$.04
2.27%
VSTM
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.08)
Revenue:  $0.00 Mil
Thursday
Feb 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VSTM reports earnings?
Beat
Meet
Miss

Where is VSTM's stock price going from here?
Up
Flat
Down
Stock chart of VSTM
Analysts
Summary of analysts' recommendations for VSTM
Score
Grade
Pivots
Resistance
$1.97
$1.91
$1.85

$1.79

Support
$1.74
$1.68
$1.62
Tweet
Growth
Description
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
Peers
Vertex PharmaceuticalsMerck & Co.Ultragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbEli LillyZoetisPfizerInterCept